Inclusion Criteria~Subjects must meet the following criteria:~1. Male or female aged 45 years and over.~2.
Female participants must be of non-childbearing potential or post-menopausal for at least 2 consecutive years
or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months
prior to screening.~3. Female participants will be given a urine pregnancy test at the screening visit for
which they should test negative.~4. A) AD - CDR = 0.5 or 1. B) PD - Hoehn \& Yahr â‰¤ 4; PD criteria by
MDS-UPDRS.~5. A) AD MMSE score between the range of 18 to 28. B) PD MMSE score between the range of 18 to
30.~6. General cognition and functional performance sufficiently preserved that the subject can provide written
informed consent.~7. No evidence of current suicidal ideation or previous suicide attempt in the past month as
evaluated in the Columbia Suicide Severity Rating Scale.~8. MRI scan within the 12 months prior to screening
without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of
intervening neurological disease. Lacunes that are not believed to contribute to the subject's cognitive
impairment are permissible. If there is no MRI available within a 12-month timeframe, then an MRI must be
performed as part of the screening procedures for eligibility.~9. Stability of permitted medications prior to
screening.~ 1. Stable for at least 12 weeks: Cholinesterase inhibitors and/or memantine medication~ 2. Stable
for at least 4 weeks:~ i. Anti-parkinsonian medication ii. Anticonvulsant medications used for epilepsy or mood
stabilization; neuropathic pain indications iii. Mood-stabilizing psychotropic agents, including, but not
limited to, lithium.~10. Adequate visual and hearing ability (physical ability to perform all the study
assessments).~11. Good general health with no disease expected to interfere with the study.~12. Subjects
previously exposed to Posiphen may be included in the study.~
